---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical presentation - signs and symptoms. Topics: Asymptomatic presentation; Asymptomatic patients in a real-world HR-positive, HER2-negative cohort; Site-dependent signs and symptoms of metastatic breast cancer; Bone metastases: pain and fractures; 15 further topics. 19 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Asymptomatic presentation

> “Metastatic cancer does not always cause symptoms.”
> “When symptoms do occur, what they are like and how often you have them will depend on the size and location of the metastatic tumors.”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-2"></a>

### Asymptomatic patients in a real-world HR-positive, HER2-negative cohort

> “Overall, physicians reported that 30.9% (n = 506) of patients were asymptomatic”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-3"></a>

### Site-dependent signs and symptoms of metastatic breast cancer

> “They may be related to the primary tumour (i.e., a palpable mass in the breast or axilla) or to the secondary site of disease: skeletal pain in bone metastases, respiratory symptoms in lung or pleural disease, abdominal pain in peritoneal involvement and neurological symptoms in brain lesions.”

Source: [Benvenuti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10136132/)

<a id="topic-2.2.1.6-4"></a>

### Bone metastases: pain and fractures

> “pain and fractures, when cancer has spread to the bone”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-5"></a>

### Bone metastases: chronic pain from expanding lesions and pathologic fracture

> “Many symptoms depend on the site of metastasis, with bone being the most frequent, and commonly occur with fatigue, depression, insomnia, and pain.”
> “Bone metastases are a common cause of chronic pain, with pain resulting directly from expanding lesions, pathologic fracture, or damage to adjacent structures.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-6"></a>

### Bone metastases: bone pain as the most frequent physician-reported symptom

> “Bone pain was the most common physician-reported symptom, affecting 30.3% (n = 496) of patients, followed by change in appetite (13.2%, n = 216) and weight loss (11.6%, n = 190).”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-7"></a>

### Bone metastases: frequency in advanced disease

> “In advanced stages of breast cancer, about 65–75% of patients eventually develop BM”

Source: [Zhang et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832676/)

<a id="topic-2.2.1.6-8"></a>

### Neurological symptoms: spinal cord compression

> “Spinal cord compression occurs in 5%–20% of cancer patients at autopsy and is a medical emergency requiring prompt evaluation and treatment”
> “Patients should be evaluated for impending cord compression if there are complaints of back pain because bone metastases are present in 95% of cases.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-9"></a>

### Central nervous system metastases: headache, seizures, and dizziness

> “headache, seizures, or dizziness, when cancer has spread to the brain”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-10"></a>

### Central nervous system metastases: leptomeningeal disease

> “Leptomeningeal disease (LMD) is an aggressive complication of ABC with tumor cells infiltrating the leptomeninges, subarachnoid space, and CSF”
> “LMD is confirmed by positive CSF cytology or can be considered as probable (typical neurological signs and symptoms plus typical neuroimaging findings) or possible (atypical clinical and typical neuroimaging findings)”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.6-11"></a>

### Pulmonary and hepatic metastases: dyspnea, jaundice, and abdominal swelling

> “shortness of breath, when cancer has spread to the lung”
> “jaundice or swelling in the belly, when cancer has spread to the liver”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-12"></a>

### Respiratory symptoms: shortness of breath by treatment class

> “Shortness of breath was reported by 63.2% of those who received ET monotherapy (n = 24) and 43.4% who received ET+CDK4/6i”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-13"></a>

### Visceral crisis: organ dysfunction from rapid progression

> “Visceral crisis is usually defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention”
> “The ABC guidelines further clarified visceral crisis as defined in liver as rapidly increasing bilirubin >1.5x ULN in the absence of an obstruction, and in lung as rapidly increasing dyspnea at rest in the absence of pleural effusion”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.6-14"></a>

### Visceral crisis: frequency at diagnosis of advanced disease

> “Visceral crisis is a life-threatening clinical condition requiring urgent treatment and accounts for 10–15% of new advanced breast cancer diagnoses, mainly hormone receptor-positive/human epidermal growth factor 2 negative.”

Source: [Benvenuti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10136132/)

<a id="topic-2.2.1.6-15"></a>

### Peritoneal metastases: abdominal pain, nausea, and ascites

> “Peritoneal carcinomatosis is more common in patients with invasive lobular carcinoma”
> “Patients may present with non-specific symptoms such as abdominal pain, decreased appetite, nausea, vomiting, weight loss, increased abdominal girth. Ascites is present in 50 % of patients.”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.6-16"></a>

### Constitutional symptoms: fatigue

> “Fatigue is the most commonly reported symptom in cancer patients, with an estimated prevalence of 25%–99% during treatment and 20%–35% off treatment”
> “Potential contributing factors include the tumor burden, pain, difficulty sleeping, anemia, poor nutrition, inactivity, and other comorbid conditions.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-17"></a>

### Constitutional and psychological symptoms reported by patients with HR-positive, HER2-negative metastatic disease

> “Of the 319 patients who completed the EORTC-QLQ-C30/BR23, the most frequently-reported issues were tiredness (85.6%, n = 273), worrying about future health (75.9%, n = 242), and general worry (75.9%, n = 242; Table 2).”
> “By treatment class, pain was reported by 80.8% of those who received chemotherapy monotherapy (n = 42), compared with 51.1% of those who received other targeted therapies (n = 24) and 63.6% who received ET+CDK4/6i (n = 110).”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-18"></a>

### Psychological symptoms: depression and sleep disturbance

> “Common vegetative symptoms of depression (fatigue, loss of appetite, insomnia) may be difficult to differentiate from symptoms related to metastases.”
> “Fatigue and depression are often associated with sleep problems, whereas pain and menopausal vasomotor symptoms may interfere with sleep quantity and quality.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-19"></a>

### Locoregional symptoms: lymphedema

> “Lymphedema may develop in the upper extremity and/or trunk of the primary tumor site and can be especially disabling if associated with infection or local recurrence”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
